4844 related articles for article (PubMed ID: 3070530)
1. Adoptive therapies: quo vadis?
Clark JW; Longo DL
Pathol Immunopathol Res; 1988; 7(6):442-58. PubMed ID: 3070530
[TBL] [Abstract][Full Text] [Related]
2. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
4. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
5. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
[TBL] [Abstract][Full Text] [Related]
6. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.
Rosenberg SA; Lotze MT; Yang JC; Aebersold PM; Linehan WM; Seipp CA; White DE
Ann Surg; 1989 Oct; 210(4):474-84; discussion 484-5. PubMed ID: 2679456
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cell and interleukin-2 inhibitors: their role in adoptive immunotherapy.
Eggermont AM; Sugarbaker PH
Cell Immunol; 1987 Jul; 107(2):384-94. PubMed ID: 3496163
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
9. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Rosenberg SA
Ann Surg; 1988 Aug; 208(2):121-35. PubMed ID: 3041925
[TBL] [Abstract][Full Text] [Related]
10. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine activated killer (LAK) cell-mediated endothelial injury: a mechanism for capillary leak syndrome in patients treated with LAK cells and interleukin-2.
Kotasek D; Vercellotti GM; Ochoa AC; Bach FH; Jacob HS
Trans Assoc Am Physicians; 1987; 100():21-7. PubMed ID: 3502662
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. [LAK cells and cancer].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3327-33. PubMed ID: 3539024
[TBL] [Abstract][Full Text] [Related]
15. [Antitumor action of interleukin 2 and its biological activities].
Hamuro J
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2111-8. PubMed ID: 3496854
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
[TBL] [Abstract][Full Text] [Related]
17. An explanation of the variable clinical response to interleukin 2 and LAK cells.
Parmiani G
Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
20. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]